Autoimmune Conditions and the Heart

This piece is for general information and discussion only. It is not medical or legal advice.

1. Context and why this matters for women’s safety

This page focuses specifically on autoimmune related cardiac risk, building on themes covered in the general women’s heart disease section.

Autoimmune conditions disproportionately affect women. NHS and epidemiological data estimate that around 70 to 80 percent of people living with autoimmune disease are female. Several of these conditions have well recognised cardiovascular implications. The relationship is clinically important because women’s cardiac symptoms are more likely to be atypical, to be misattributed to anxiety, or to be diagnosed later than men’s. National cardiovascular reviews highlight that inflammatory mechanisms can accelerate atherosclerosis, affect heart valves, and disrupt heart rhythm in ways that may not be immediately recognised, especially in younger women or those with non classic symptoms.

Despite this, system reviews repeatedly show that autoimmune related cardiac risk is inconsistently assessed or coded in primary and secondary care records. Delays in recognising myocarditis, pericarditis, microvascular dysfunction or thrombotic risk have appeared in coroners’ findings, safety reviews and NHS Resolution data.

These cases often involve conditions such as:
• Lupus (a chronic autoimmune disease where the immune system attacks healthy tissues, causing widespread inflammation, fatigue, joint pain, and characteristic butterfly-shaped facial rashes)
• Antiphospholipid syndrome (an autoimmune disorder where the immune system creates antibodies that mistakenly attack phospholipids, causing blood to clot inappropriately in arteries and veins)
• Rheumatoid arthritis (a chronic autoimmune disease where the immune system attacks joint linings (synovium), causing painful, stiff, and swollen joints)
• Vasculitides (a group of around 20 rare autoimmune diseases characterised by blood vessel inflammation, causing weakened walls, narrowed vessels, and organ damage)

The challenge is not a lack of clinical knowledge but a failure to integrate that knowledge across specialties, especially where women’s multisystem symptoms are dismissed or siloed.

2. Evidence, guidance and policy

National guidance emphasises that safe assessment involves recognising the systemic nature of autoimmune disease and its interaction with the cardiovascular system. Relevant NICE guidance on connective tissue disorders, inflammatory arthritis, and chest pain recommends structured assessment for inflammation, thrombosis risk, and cardiac involvement. Royal College and NHS England documents underline the importance of early investigation when symptoms such as breathlessness, chest discomfort, palpitations or syncope arise in people with known autoimmune disease.

Key clinical considerations highlighted in guidance

Guidance notes that clinicians typically assess:
• inflammatory burden and disease activity, which can affect endothelial function and accelerate coronary disease
• risk of autoimmune myocarditis or pericarditis, especially during flares
• thrombotic risk in conditions such as antiphospholipid syndrome
• microvascular angina, which is more common in women and often missed
• medication effects, including steroids and immunosuppressants, which may contribute to hypertension, dyslipidaemia or fluid retention
• interactions between hormonal transitions (pregnancy, menopause) and autoimmune disease activity

National reviews also highlight diagnostic overshadowing, where symptoms attributed to autoimmune flares may in fact represent cardiac pathology. NHS England’s work on women’s cardiovascular health stresses the need for structured history taking and awareness of non classic symptom patterns.

Pregnancy and postnatal context

Pregnancy brings unique risks for women with autoimmune conditions, particularly lupus and antiphospholipid syndrome. MBRRACE UK reports note that cardiac disease remains a leading cause of maternal death. Autoimmune related thrombosis, cardiomyopathy, pulmonary hypertension and pericardial involvement appear across several reports. National maternity guidance encourages close multidisciplinary planning, early recognition of cardiac symptoms and careful attention to postpartum deterioration, where inflammation and haemodynamic changes can unmask cardiac disease.

3. What women often describe raising

Investigations and research repeatedly note that women often report:
• long diagnostic journeys, where early symptoms are interpreted as stress or musculoskeletal pain
• difficulty accessing joined up rheumatology and cardiology assessment
• concerns about palpitations, chest pressure or breathlessness that did not lead to timely investigation
• challenges having cardiac risk taken seriously at younger ages
• fragmented follow up when care is divided between specialities with no single coordinator
• uncertainty about whether symptoms represent autoimmune flare, medication effects or something new

National reviews describe many women saying they struggled to have cardiovascular symptoms differentiated from fatigue, anaemia or anxiety. Several inquiries point to the cumulative impact of bias, atypical presentation and implicit assumptions about age related risk.

4. System watchpoints (for information only)

This section highlights system patterns seen in research, guidance and investigations. It is not medical or legal advice, and it is not a checklist for your own care.

Who the evidence represents

Much of the literature centres on lupus, rheumatoid arthritis and antiphospholipid syndrome. Evidence for rarer autoimmune conditions remains sparse. Younger women and those from minoritised ethnic groups are often under represented despite carrying higher disease burdens.

Coding and data continuity

Several reviews identify that autoimmune diagnoses are not consistently coded across GP, rheumatology and cardiology systems. Missing or outdated coding affects risk assessment, prescribing and clinical alerts.

Dose and monitoring

Steroid related cardiovascular risk is well documented, yet monitoring arrangements vary across the NHS. Some reviews highlight gaps in lipid monitoring, blood pressure reviews and tapering plans.

Digital design

Algorithms for chest pain and emergency triage rely on age based stratification that may under recognise autoimmune cardiac risk in women under 55. Digital tools often lack fields for disease activity scores or flare indicators.

Transitions of care

Transitions between paediatric and adult rheumatology, and between secondary and tertiary cardiology, are identified as high risk periods. Several reports highlight missed referrals and unclear ownership of complex cases.

5. What is improving

• NHS England’s women’s cardiovascular programme is increasing awareness of atypical presentation.
• Updated NICE guidance on chest pain includes microvascular angina, which is more common in women.
• New HSSIB investigations on diagnostic delay are promoting cross specialty coordination.
• Increasing use of multidisciplinary clinics for autoimmune conditions, including better integration of cardiology input.

6. Where further improvement might come from

• More systematic cardiovascular screening pathways for high risk autoimmune groups.
• Routine inclusion of autoimmune disease indicators in primary care risk algorithms.
• Clearer shared care protocols between rheumatology, cardiology and primary care.
• Better digital interoperability to ensure disease activity and flare information is visible to all clinicians involved.
• Expansion of pregnancy cardiology services to incorporate autoimmune specialists.

7. Reflective questions (off blog only, no personal data)

For clinicians

How consistently is autoimmune status coded and visible at the point of triage?
Are cardiovascular risks discussed and documented at stable disease visits?
How are atypical or recurrent chest symptoms escalated in younger women?
Do current pathways enable timely cross specialty review?
How is postpartum autoimmune cardiac risk incorporated into local maternity governance?

For patients and the public

Are published NHS materials clear about the interaction between autoimmune conditions and the heart?
Do care pathways feel joined up when symptoms span multiple systems?
Is communication trauma aware and free from dismissal?
Are flare patterns and symptom changes routinely explored?
Are transitions of care explained in clear, accessible language?

Mandatory disclaimer

This article is for general information and discussion only. It is not medical or legal advice, nor a substitute for professional advice. To contribute evidence, ideas, or corrections, please email womenshealthproject@outlook.com. Please do not share personal data when emailing. Individual cases cannot be reviewed. This project does not offer any form of legal service and cannot assist with complaints, claims or individual advocacy.

This platform is independent and not affiliated with any law firm, regulator, inquiry or clinical body.

References

NICE. Chest pain of recent onset: assessment and diagnosis. Available at: https://www.nice.org.uk/guidance/cg95
NICE. Rheumatoid arthritis in adults. Available at: https://www.nice.org.uk/guidance/ng100
NHS England. Women’s Health Strategy and cardiovascular disease programme. Available at: https://www.england.nhs.uk
MBRRACE UK. Saving Lives, Improving Mothers’ Care. Available at: https://www.npeu.ox.ac.uk/mbrrace-uk
HSSIB. Investigations into delayed diagnosis and system coordination. Available at: https://www.hssib.org.uk